REPLY: Novel Technologies Must Be Considered for Childhood Cancer Survivors at Risk for Cardiomyopathy

Detalles Bibliográficos
Autores principales: Aziz-Bose, Rahela, Armenian, Saro H., Nohria, Anju, Kenney, Lisa B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2023
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9982201/
https://www.ncbi.nlm.nih.gov/pubmed/36875896
http://dx.doi.org/10.1016/j.jaccao.2022.12.004
_version_ 1784900281183502336
author Aziz-Bose, Rahela
Armenian, Saro H.
Nohria, Anju
Kenney, Lisa B.
author_facet Aziz-Bose, Rahela
Armenian, Saro H.
Nohria, Anju
Kenney, Lisa B.
author_sort Aziz-Bose, Rahela
collection PubMed
description
format Online
Article
Text
id pubmed-9982201
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-99822012023-03-04 REPLY: Novel Technologies Must Be Considered for Childhood Cancer Survivors at Risk for Cardiomyopathy Aziz-Bose, Rahela Armenian, Saro H. Nohria, Anju Kenney, Lisa B. JACC CardioOncol Letter to the Editor Elsevier 2023-02-21 /pmc/articles/PMC9982201/ /pubmed/36875896 http://dx.doi.org/10.1016/j.jaccao.2022.12.004 Text en © 2023 The Authors https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Letter to the Editor
Aziz-Bose, Rahela
Armenian, Saro H.
Nohria, Anju
Kenney, Lisa B.
REPLY: Novel Technologies Must Be Considered for Childhood Cancer Survivors at Risk for Cardiomyopathy
title REPLY: Novel Technologies Must Be Considered for Childhood Cancer Survivors at Risk for Cardiomyopathy
title_full REPLY: Novel Technologies Must Be Considered for Childhood Cancer Survivors at Risk for Cardiomyopathy
title_fullStr REPLY: Novel Technologies Must Be Considered for Childhood Cancer Survivors at Risk for Cardiomyopathy
title_full_unstemmed REPLY: Novel Technologies Must Be Considered for Childhood Cancer Survivors at Risk for Cardiomyopathy
title_short REPLY: Novel Technologies Must Be Considered for Childhood Cancer Survivors at Risk for Cardiomyopathy
title_sort reply: novel technologies must be considered for childhood cancer survivors at risk for cardiomyopathy
topic Letter to the Editor
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9982201/
https://www.ncbi.nlm.nih.gov/pubmed/36875896
http://dx.doi.org/10.1016/j.jaccao.2022.12.004
work_keys_str_mv AT azizboserahela replynoveltechnologiesmustbeconsideredforchildhoodcancersurvivorsatriskforcardiomyopathy
AT armeniansaroh replynoveltechnologiesmustbeconsideredforchildhoodcancersurvivorsatriskforcardiomyopathy
AT nohriaanju replynoveltechnologiesmustbeconsideredforchildhoodcancersurvivorsatriskforcardiomyopathy
AT kenneylisab replynoveltechnologiesmustbeconsideredforchildhoodcancersurvivorsatriskforcardiomyopathy

Ejemplares similares